Scopus İndeksli Yayınlar Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/20.500.14627/7
Browse
3 results
Search Results
Article Novel Hydrazide-Hydrazone Derivatives Containing Flurbiprofen 1,2,4-Triazole as Anticancer Agents: Design, Synthesis and Biological Evaluation(Slovensko Kemijsko Drustvo, 2026) Küçükgüzel, Ş. Güziz; Gökoğlan, Ecem; Yılmaz, Özgür; Çevik, Özge; Çakıcı, Çiğdem; Erdoğan, ÖmerHydrazone derivatives are one of the scaffolds frequently used in new drug development studies. Due to the promising pharmacological effects of the hydrazone structure, fifteen new hydrazide-hydrazone compounds containing flurbiprofen 1,2,4-triazole were synthesized in this study and their in vitro anticancer effects were tested. All compounds were tested for cytotoxic effects against breast cancer cell lines (MCF-7 and MDA-MB231), and glioblastoma cell line (U87) by using MTT assay. Among the synthesized compounds, compounds 7a and 7c exhibited the most potent cytotoxic activity with IC50 values of 7.80 +/- 1.20 & micro;M and 2.40 +/- 0.93 & micro;M against MCF-7 cell line, while compound 7a showed the highest activity with IC50 value of 7.63 +/- 1.05 & micro;M against MDA-MB231 cell line. In addition, compounds 7c and 7n presented cytotoxic activity with IC50 values of 10.31 +/- 4.63 & micro;M and 10.81 +/- 6.11 & micro;M against U87 cell line. The possible cytotoxic effects of compounds on mouse fibroblast cell line (L929) were assessed for their safety and compounds 7a, 7c, and 7n were found less toxic than 5-fluorourasil. Additionally, compound 7c was further studied to investigate its effects on apoptosis and PI3K activity, which play a role in cancer development. The results showed that compound 7c increased apoptosis in MCF-7 cells and it displayed PI3K enzyme inhibitory activity. Our study revealed that the synthesized hydrazone compounds have the potential to be lead compounds for further studies on cancer.Article Comparative Evaluation of Vision Transformers and Convolutional Networks for Breast Ultrasound Image Classification(Open Exploration Publishing Inc, 2026) Naral S.; Cakmak Y.; Pacal I.; Pacal, Ishak; Cakmak, Yigitcan; Naral, SuleymanAim: Interobserver variability continues to limit the consistency of breast ultrasound interpretation. This study compares two Vision Transformer (ViT) models and two Convolutional Neural Network (CNN) models for automated three-class breast ultrasound classification, with a specific focus on the tradeoff between predictive performance and computational efficiency. Methods: Swin Transformer Base and DeiT Base were evaluated alongside InceptionV3 and MobileNetV3 Large using the public Breast Ultrasound Images (BUSI) dataset, which contains 780 images labeled as benign, malignant, and normal. A consistent on-the-fly augmentation pipeline was applied during training to promote robustness and reduce sensitivity to incidental image variations. Results: Swin Transformer Base achieved the highest test accuracy (0.9167) and F1 score (0.8981). MobileNetV3 Large reached an accuracy of 0.8583 with substantially lower computational demand. The efficiency contrast was pronounced, with Swin requiring 30.33 GFLOPs versus 0.43 GFLOPs for MobileNetV3 Large. Conclusions: On this benchmark, ViT models can yield higher classification performance, while lightweight CNNs offer a strong efficiency profile that may better match deployment-constrained settings. These results suggest that model selection should be guided by both predictive accuracy and operational feasibility within the target clinical workflow. © The Author(s) 2026.Article Citation - WoS: 2Citation - Scopus: 3Biological Activities of Etodolac-Based Hydrazone, Thiazolidinone and Triazole Derivatives on Breast Cancer Cell Lines MCF-7 and MDA-MB(Wiley, 2025) Sevinc, Sevgi Kocyigit; Cikla-Suzgun, Pelin; Tiber, Pinar Mega; Kucukguzel, S. Guniz; Orun, Oya; Güniz Küçükgüzel, Ş.In this study, several etodolac-based hydrazone, thiazolidinone, and triazole derivatives that we synthesized and characterized in our earlier research were tested against the hormone-responsive breast cell line MCF-7 and the triple-negative MDA-MB-231, as well as the murine origin fibroblast cell line L-929, at varying doses for their effects on cell viability and toxicity and for their inhibitory activity on cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) formation. Cell viability and apoptosis tests were utilized to assess the anti-cancer potential of etodolac and its derivatives after the cells were exposed to varied concentrations of synthesized compounds for three different time periods. ELISA and Western blot methods were used to detect protein levels. All synthesized compounds demonstrated higher anti-cancer activity at significantly lower doses compared to etodolac (half-maximal inhibitory concentration [IC50] of 0-50 mu M range in derivatives versus 0.5-1 mM range in etodolac). Except for SGK 242, which had a major toxic effect on all cells, the chemicals SGK 206 and SGK 217 had a twice-less impact on control murine L-929 fibroblasts. Similar to proliferation, low concentrations of SGK 206 and SGK 217 (25-50 mu M) significantly induced apoptosis in breast cancer cells but not in normal cells. Additionally, they inhibited COX-2 protein expression at 50 mu M, and SGK 206 inhibited PGE2 release more effectively than etodolac in cancer cells. The results of this study suggest that, in comparison to a healthy control group, the thiazolidinone derivative SGK 206 and the thiazolidinone derivative SGK 217 are more effective than etodolac when it comes to the breast cancer cell lines MCF-7 and MDA-MB-231. SGK 206 exhibits a low IC50 value, a distinct dose-response relationship, and strong apoptotic effects, particularly on MDA-MB-231 cells.